Title |
Intervention | NCT ID | Sponsor | Status |
|---|---|---|---|---|
| Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients | Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine | NCT03036930 | National Cancer Institute (NCI) | Active, not recruiting |
| Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection... | Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate | NCT03887702 | Southwest Oncology Group | Recruiting |
| PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer... | Laboratory Biomarker Analysis, Rilimogene Galvacirepvec, Placebo Administration | NCT02326805 | National Cancer Institute (NCI) | Active, not recruiting |
| Radiation Therapy in Treating Patients With Prostate Cancer | 36.25 Gy IMRT, 51.6 Gy IMRT | NCT01434290 | Radiation Therapy Oncology Group | Active, not recruiting |
| Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger... | Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine | NCT02568566 | National Cancer Institute (NCI) | Active, not recruiting |
| Relaxation for Women With Breast Cancer Undergoing Radiotherapy | Relaxation Program, Questionnaires, Saliva Testing | NCT01202851 | M.D. Anderson Cancer Center | Active, not recruiting |
| Reproductive Health Program in Patients With Cancer | educational intervention, quality-of-life assessment, questionnaire administration | NCT01806129 | Eastern Cooperative Oncology Group | Active, not recruiting |
| Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | Retinoid 9cUAB30, Therapeutic Conventional Surgery | NCT02876640 | National Cancer Institute (NCI) | Recruiting |
| Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 | Electronic Health Record Review | NCT04674228 | National Cancer Institute (NCI) | Recruiting |
| S0820, Adenoma and Second Primary Prevention Trial | Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac | NCT01349881 | Southwest Oncology Group | Recruiting |
Why I Joined a Clinical Trial
I participated in the trial because I wanted to honor the women that had come before and helped me have so many amazing treatment options. I also have friends who stopped taking Tamoxifen because they could not handle the side effects, and I really want my niece and her generation to have better alternatives if they ever need them.